There are too many stories out there to cover them all, but some are just too important to ignore, even if we get to them a little later than we’d like.
Findings on a new anti-HIV gel were released on Monday, and more thoroughly presented yesterday. Wife-and-husband team Quarraisha and Salim Abdool Karim lead the research, and their studies indicate that, when administered in a vaginal gel, the drug tenofovir decreases a woman’s risk of contracting the virus by 39% (keeping in mind that consistency of use in the test group was unknown). While not a magic bullet, the idea of a woman-controlled and -administered anti-viral drug that can significantly decrease the risk of a disease that disproportionately affects women promises to be revolutionary. Extra super special bonus? The gel was even more effective against the herpes virus!
More testing in needed, and the concentration of tenofovir may need to be increased, but this news is nothing but good for those working to defeat HIV/AIDS. …Or is it? I’ve already seen some skepticism about these results. Can some of our harpy scientists weigh in on methodology of these studies?